Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;89(5):1560-1574.
doi: 10.1111/bcp.15611. Epub 2022 Dec 16.

COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort

Guillaume Favre  1 , Eva Gerbier  1   2 , Emeline Maisonneuve  1   2 , Léo Pomar  1   3 , Ursula Winterfeld  4 , Karine Lepigeon  1 , Kitty W M Bloemenkamp  5 , Odette de Bruin  5   6 , Eimir Hurley  7 , Hedvig Nordeng  7 , Satu J Siiskonen  8 , Miriam C J M Sturkenboom  6 , David Baud  1 , Alice Panchaud  2   9 ; COVI-PREG and CONSIGN group
Collaborators, Affiliations
Free article

COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort

Guillaume Favre et al. Br J Clin Pharmacol. 2023 May.
Free article

Abstract

Aim: The objective of this study was to describe the use of COVID-19-related medicines during pregnancy and their evolution between the early/late periods of the pandemic.

Methods: Pregnant women who tested positive for SARS-CoV-2 from March 2020 to July 2021 were included using the COVI-PREG registry. Exposure to the following COVID-19-related medicines was recorded: antibiotics, antivirals, hydroxychloroquine, corticosteroids, anti-interleukin-6 and immunoglobulins. We described the prevalence of medicines used, by trimester of pregnancy, maternal COVID-19 severity level and early/late period of the pandemic (before and after 1 July 2020).

Findings: We included 1964 pregnant patients who tested positive for SARS-CoV-2. Overall, 10.4% (205/1964) received at least one COVID-19-related medicine including antibiotics (8.6%; 169/1694), corticosteroids (3.2%; 62/1964), antivirals (2.0%; 39/1964), hydroxychloroquine (1.4%; 27/1964) and anti-interleukin-6 (0.3%; 5/1964). The use of at least one COVID-19-related medicine was 3.1% (12/381) in asymptomatic individuals, 4.2% (52/1233) in outpatients, 19.7% (46/233) in inpatients without oxygen, 72.1% (44/61) in those requiring standard oxygen, 95.7% (22/23) in those requiring high flow oxygen, 96.2% (25/26) in patients who required intubation and 57.1% (4/7) among patients who died. The proportion who received medicines to treat COVID-19 was higher before than after July 2020 (16.7% vs. 7.7%). Antibiotics, antivirals and hydroxychloroquine had lower rates of use during the late period.

Conclusion: Medicine use in pregnancy increased with disease severity. The trend towards increased use of corticosteroids seems to be aligned with changing guidelines. Evidence is still needed regarding the effectiveness and safety of COVID-19-related medicines in pregnancy.

Keywords: COVID-19; COVID-19-related medicine; SARS-CoV-2; drug use; medicine use; pharmaco-epidemiology; pregnancy.

PubMed Disclaimer

References

REFERENCES

    1. Favre G, Pomar L, Baud D. Coronavirus disease 2019 during pregnancy: do not underestimate the risk of maternal adverse outcomes. Am J Obstet Gynecol MFM. 2020;2(3):100160. doi:10.1016/j.ajogmf.2020.100160
    1. Vouga M, Favre G, Martinez-Perez O, et al. Maternal outcomes and risk factors for COVID-19 severity among pregnant women. Sci Rep. 2021;11(1):13898. doi:10.1038/s41598-021-92357-y
    1. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. doi:10.1136/bmj.m3320
    1. Villar J, Ariff S, Gunier RB, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID Multinational Cohort Study. JAMA Pediatr. 2021;175(8):817-826. doi:10.1001/jamapediatrics.2021.1050
    1. Sankaran D, Nakra N, Cheema R, Blumberg D, Lakshminrusimha S. Perinatal SARS-CoV-2 infection and neonatal COVID-19: a 2021 update. Neoreviews. 2021;22(5):e284-e295. doi:10.1542/neo.22-5-e1001

Publication types